Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blindness may boost your sense of taste and smell, scientists say

NCT ID NCT07707219

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study investigates whether people with central or peripheral vision loss develop heightened senses of taste and smell. Researchers will measure brain responses to sweet and vanilla flavors in 50 visually impaired adults and compare them to sighted controls. The goal is to understand how the brain adapts to vision loss by enhancing other senses, which could influence food choices and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If it works, this could reveal how the brain compensates for vision loss by sharpening other senses, potentially guiding new approaches to help people with visual impairments.
What could go wrong
This is a small observational study with only 50 participants, so results may not apply to everyone. It measures brain activity, not real-world eating behavior, so practical benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult: ≥ 18 years and ≤ 60 years * Individual who has given oral consent * Individual who has been fasting (no food, drink, or tobacco) for at least 1 hour prior to PEG and PEO measurement * No cognitive complaints and normal neurological examination. * Group of patients with visual impairment: A. Central: documented bilateral macular dystrophy (e.g., Stargardt disease, Best disease) with confirmed central scotoma (CV 24.2, 10.2, or 30.2). B. Peripheral: documented bilateral peripheral retinal dystrophy with confirmed peripheral involvement (CV 30-2 or 24-2). • Control group: a person with normal vision and no known ophthalmological abnormalities (normal visual acuity and fundus examination) who is precisely matched by sex and smoking status (former smoker who has quit vs. nonsmoker), and approximately matched by age (± 5 years) to a visually impaired participant included in the study. Exclusion Criteria: For this group: patients with visual impairments: * Individuals who are not enrolled in or eligible for a social security program * Individuals subject to a legal protective measure (guardianship, conservatorship) * Individuals subject to judicial safeguard measures * Adults who are legally incapacitated or unable to give informed consent * Documented COVID-19 infection within the 6 months prior to enrollment * Active smokers (≥1 cigarette per day) or users of any other inhaled substances (water pipe, cannabis, etc.) * Participants following a sugar-free diet * Participants with diabetes, of any type * Participants taking medication (ongoing during the study) that interferes with taste perception • Pregnant or breastfeeding women * Individuals with neurodegenerative diseases (Parkinson's, Alzheimer's) * Individuals with braids, dreadlocks, or any other hairstyle that prevents electrodes from being placed in sufficiently precise locations on the scalp. * Overweight subjects with a BMI ≥ 35 kg/m²

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central visual impairment are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chu Dijon Bourgogne

    Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.